A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)

A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)

Abstract Background Targeting RAS mutant (MT) colorectal cancer (CRC) remains a difficult challenge, mainly due to the pervasiveness of RAS/MEK-mediated feedback loops. Preclinical studies identified MET/STAT3 as an important mediator of resistance to KRAS-MEK1/2 blockade in RASMT CRC. This dose esc...

Full description

Saved in:
Bibliographic Details
Main Authors: Francesca Aroldi, Elena Elez, Thierry André, Geraldine Perkins, Hans Prenen, Vlad Popovici, Peter Gallagher, Jennifer Houlden, Linda Collins, Corran Roberts, Christian Rolfo, Federica Di Nicolantonio, Margaret Grayson, Ruth Boyd, Karolien Bettens, Jurgen Delfavero, Victoria Coyle, Mark Lawler, Hajrah Khawaja, Pierre Laurent-Puig, Manuel Salto-Tellez, Tim S. Maughan, Josep Tabernero, Richard Adams, Robert Jones, Bryan T. Hennessy, Alberto Bardelli, Marc Peeters, Mark R. Middleton, Richard H. Wilson, Sandra Van Schaeybroeck, on behalf of the MErCuRIC Trial Consortium
Format: Article
Language:English
Published: BMC 2025-04-01
Series:BMC Cancer
Subjects:
RAS mutant
Colorectal cancer
Phase I
Binimetinib
Crizotinib
Pharmacokinetics
Online Access:https://doi.org/10.1186/s12885-025-14068-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items